18 January 2020 - Pharma giants that used to profit from off-patent drugs forced to compete with local generic makers.

Global pharmaceutical majors and generic drugmakers have slashed the prices of some of their off-patent products by an average of 53% in the latest bidding round under China’s national bulk-buying programme.

Beijing has been pushing forward a system that requires drugmakers to go through a bidding process and cut prices low enough to be considered over generic copies if they want to sell their products at public hospitals via large-volume government procurement.

Read Bangkok Post article